Viruses of the Caliciviridae cause significant and sometimes lethal diseases, however despite substantial research efforts, specific antivirals are lacking. Broad-spectrum antivirals could combat multiple viral pathogens, offering a rapid solution when no therapies exist. The RNA-dependent RNA polymerase (RdRp) is an attractive antiviral target as it is essential for viral replication and lacks mammalian homologs. To focus the search for pan-Caliciviridae antivirals, the RdRp was probed with non-nucleoside inhibitors (NNIs) developed against hepatitis C virus (HCV) to reveal both allosteric ligands for structure-activity relationship enhancement, and highly-conserved RdRp pockets for antiviral targeting. The ability of HCV NNIs to inhibit calicivirus RdRp activities was assessed using in vitro enzyme and murine norovirus cell culture assays. Results revealed that three NNIs which bound the HCV RdRp Thumb I (TI) site also inhibited transcriptional activities of six RdRps spanning the Norovirus, Sapovirus and Lagovirus genera of the Caliciviridae. These NNIs included JTK-109 (RdRp inhibition range: IC 50 4.3 e16.6 mM), TMC-647055 (IC 50 range: 18.8e45.4 mM) and Beclabuvir (IC 50 range: 23.8e>100 mM). In silico studies and site-directed mutagenesis indicated the JTK-109 binding site was within the calicivirus RdRp thumb domain, in a pocket termed Site-B, which is highly-conserved within all calicivirus RdRps. Additionally, RdRp inhibition assays revealed that JTK-109 was antagonistic with the previously reported RdRp inhibitor pyridoxal-5 0 -phosphate-6-(2 0 -naphthylazo-6 0 -nitro-4 0 ,8 0 -disulfonate) tetrasodium salt (PPNDS), that also binds to Site-B. Moreover, like JTK-109, PPNDS was also a potent inhibitor of polymerases from six viruses spanning the three Caliciviridae genera tested (IC 50 range: 0.1e2.3 mM).
a b s t r a c t
Viruses of the Caliciviridae cause significant and sometimes lethal diseases, however despite substantial research efforts, specific antivirals are lacking. Broad-spectrum antivirals could combat multiple viral pathogens, offering a rapid solution when no therapies exist. The RNA-dependent RNA polymerase (RdRp) is an attractive antiviral target as it is essential for viral replication and lacks mammalian homologs. To focus the search for pan-Caliciviridae antivirals, the RdRp was probed with non-nucleoside inhibitors (NNIs) developed against hepatitis C virus (HCV) to reveal both allosteric ligands for structure-activity relationship enhancement, and highly-conserved RdRp pockets for antiviral targeting. The ability of HCV NNIs to inhibit calicivirus RdRp activities was assessed using in vitro enzyme and murine norovirus cell culture assays. Results revealed that three NNIs which bound the HCV RdRp Thumb I (TI) site also inhibited transcriptional activities of six RdRps spanning the Norovirus, Sapovirus and Lagovirus genera of the Caliciviridae. These NNIs included JTK-109 (RdRp inhibition range: IC 50 4.3 e16.6 mM), range: 18.8e45.4 mM) and Beclabuvir (IC 50 range: 23.8e>100 mM). In silico studies and site-directed mutagenesis indicated the JTK-109 binding site was within the calicivirus RdRp thumb domain, in a pocket termed Site-B, which is highly-conserved within all calicivirus RdRps. Additionally, RdRp inhibition assays revealed that JTK-109 was antagonistic with the previously reported RdRp inhibitor pyridoxal-5 0 -phosphate-6-(2 0 -naphthylazo-6 0 -nitro-4 0 ,8 0 -disulfonate) tetrasodium salt (PPNDS) , that also binds to Site-B. Moreover, like JTK-109, PPNDS was also a potent inhibitor of polymerases from six viruses spanning the three Caliciviridae genera tested (IC 50 range: 0.1e2.3 mM).
Together, this study demonstrates the potential for de novo development of broad-spectrum antivirals that target the highly-conserved RdRp thumb pocket, Site-B. We also revealed three broad-spectrum HCV NNIs that could be used as antiviral scaffolds for further development against caliciviruses and other viruses.
© 2017 Elsevier B.V. All rights reserved.
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Introduction
There is currently a lack of both narrow and broad-spectrum antivirals (BS-AVs) available to combat viral pathogens (Debing et al., 2015) . This deficiency of BS-AVs is due to the complexity of viral replication strategies and their various host tropisms (Martinez et al., 2015) . Antivirals are generally targeted against a single viral species, for example: hepatitis B virus (HBV), hepatitis C virus (HCV), herpesviruses or human immunodeficiency virus (HIV) (Gotte and Feld, 2016; Murakami et al., 2015; Cihlar and Fordyce, 2016) , and cross-species antiviral activity is rare. BS-AVs could be used to combat several clinically significant and emerging viral pathogens when no specific therapies exist (Debing et al., 2015) . Additionally, they could be used as prophylaxis in an outbreak setting, to treat chronically infected patients, or when rapid and accurate diagnoses are not feasible (Warren et al., 2014) . Given the global health burden created by caliciviruses, there is a necessity to develop safe and effective BS-AVs against all Caliciviridae pathogens.
One strategy in BS-AV development is to target conserved domains of viral enzymes critical for replication (Debing et al., 2015) . The viral RNA-dependent RNA polymerase (RdRp) is an attractive antiviral target, given its highly-conserved structure across viral families. RdRps are essential for viral replication and largely lack host homologs, minimizing chances of off-target effects (Malet et al., 2008) . Despite significant sequence diversity, all RdRps form structural homomorphs resembling a closed right-hand with fingers, palm and thumb domains (Ng et al., 2008; Ferrer-Orta et al., 2006) . To identify broadly conserved RdRp regions for further antiviral targeting, bioactive molecules can be identified by screening compounds or libraries using polymerase assays with RdRps from several viral species (Gong et al., 2013) . This approach can reveal both highly-conserved viral enzyme domains, and BS-AV candidates with activity against different species, genera and families.
Caliciviruses are a diverse family of positive-sense RNA viruses, currently classified into five genera; Norovirus, Sapovirus, Lagovirus, Nebovirus and Vesivirus (Clarke et al., 2012) . Viruses from the Caliciviridae cause significant diseases in a wide range of vertebrate hosts (Clarke and Lambden, 1997) , and the substantial impact caused by caliciviruses is often underestimated (van Asten et al., 2011; Lee et al., 2012; Delibes-Mateos et al., 2014) . Currently there are no specific antivirals available for the treatment of calicivirus infections, and vaccines are only available for two viruses, feline calicivirus (FCV) and rabbit hemorrhagic disease virus (RHDV) (Radford et al., 2006; Abrantes et al., 2012) .
Among the caliciviruses that infect humans, norovirus (NoV) is a leading cause of acute gastroenteritis (Koo et al., 2010; Ahmed et al., 2014) , accounting for approximately 219,000 deaths annually (Bartsch et al., 2016) . Antiviral development faces significant challenges, partly because a cell culture system to propagate human NoV was only recently established (Jones et al., 2014; Ettayebi et al., 2016) . Consequently, much of what is known about human NoV biology has been inferred from other caliciviruses including FCV and murine norovirus (MNV) (Karst et al., 2003) . Both viruses are easily cultured, and MNV in particular has been widely used to screen potential human NoV antivirals in cell culture and mouse models (Wobus and Thackray, 2006) .
Other significant Caliciviridae pathogens include sapovirus (SaV), FCV, and RHDV. SaV infects a wide range of species including humans, swine and marine mammals (Tse et al., 2012) , whilst RHDV is a highly contagious pathogen that has been used as an effective rabbit biocontrol agent (Green et al., 2000) . Together with benign rabbit calicivirus (RCV), RHDV is a member of the Lagovirus genus that infects the European rabbit, Oryctolagus cuniculus (Capucci et al., 1996) .
Non-nucleoside inhibitors (NNIs) are antivirals that bind to the RdRp allosterically, preventing polymerase conformational changes required for replication (Caillet-Saguy et al., 2011) . All clinically approved NNIs to-date offer only narrow-spectrum, species-specific activity, developed against either HIV (US Food and Drug Administration, 2014) or HCV (Hepatitis C Support Project, 2016). The HCV RdRp has five defined NNI binding sites (Eltahla et al., 2015) including: Thumb I (TI), Thumb II (TII), Palm I (PI), Palm II (PII) and Palm b (Pb) (Fig. 1A) . Previously, we reported that HCV TIand PII-binding NNIs exhibit cross-genotypic activity against HCV (Eltahla et al., 2014a) , indicating the potential for a wider antiviral spectrum. To identify broad-spectrum calicivirus RdRp targets, we used HCV NNIs as an initial probe for inhibitory activity against the human NoV RdRp, and then against a range of caliciviral RdRps.
Whilst HCV NNI RdRp binding sites are well defined, much less is known about the human NoV RdRp. Currently only three human (Eltahla et al., 2015) . B) Inhibitory effects of six HCV NNIs on human NoV GII.4 Den Haag 2006b RdRp activity were examined using a fluorescence-based RdRp transcription assay. NNIs (0.01 pMe100 mM) were compared to samples containing the compound vehicle only (0.5% DMSO [vol/vol] NoV NNI binding sites have been described, largely because few NoV NNIs have been reported (Eltahla et al., 2014b) . These three NoV RdRp NNI binding sites include one site across the fingers and thumb domains in the RdRp NTP access pathway Mastrangelo et al., 2012) , and two binding sites in the thumb domain, named Site-A and Site-B .
Site-A is a positively charged cleft for NTP traversal, with flexible amino acid side chains . This flexibility poses challenges to structure-based antiviral development; therefore Site-A is less attractive than Site-B as an antiviral target site .
Co-crystallization studies of the human NoV RdRp and suramin were used to identify its binding pocket in the NTP access pathway between the fingers and thumb domains (Mastrangelo et al., 2012) . Other examples of compounds that bind in each NNI site include suramin derivatives such as NF023 which binds the NTP access pathway (Mastrangelo et al., 2012) ; naphthalene di-sulfonate (NAF2) which binds in Site-A ; and NAF2 and pyridoxal-5 0 -phosphate-6-(2 0 -naphthylazo-6 0 -nitro-4 0 ,8 0 -disulfonate) tetrasodium salt (PPNDS; Table 1) which both bind in Site-B .
However, suramin and its derivatives, including PPNDS, are poor drug candidates, demonstrating cell permeability issues due to the negative charges on the sulfonate groups (Beindl et al., 1996; Klinger et al., 2001) , thus limiting bioavailability and antiviral efficacy in viral culture (Croci et al., 2014a) . Additionally, PPNDS has been eliminated from other studies due to non-specific, off-target activities (Simeonov et al., 2009) , and therefore it lacks the druglike properties required for further antiviral development.
PPNDS was first reported as a potent P2X1 receptor agonist (Lambrecht et al., 2000) , but subsequently demonstrated potent inhibition of human NoV and MNV RdRps Croci et al., 2014b) with IC 50 values between 0.45 and 0.88 mM Croci et al., 2014b) . Co-crystallization studies with the human NoV RdRp showed that PPNDS notably interacts with the Site-B amino acids Q414 and R419, amongst others . PPNDS reportedly inhibits transcription by fixing the C-terminal end of the RdRp within the active site, blocking the incoming RNA template and NTPs .
In this study, we aimed to identify broadly-active NNI scaffolds for further antiviral development. Representative HCV NNIs were used to probe calicivirus RdRps from the Norovirus, Sapovirus and Lagovirus genera for inhibition of transcription. We identified three HCV NNIs with pan-Caliciviridae activity. The second aim of this study was to identify highly-conserved domains across calicivirus RdRps, to target for de novo BS-AV development. Using in silico studies and site-directed mutagenesis we identified Site-B as a highly-conserved, broad-spectrum calicivirus RdRp pocket, which can now be targeted for antiviral development through de novo drug design.
Materials and methods

Test compounds
Compounds (Table 1) 
Recombinant RdRp expression, purification and mutagenesis
Recombinant calicivirus RdRps (GenBank accession numbers) NoV GII.4 Den Haag 2006b (EF684915), NoV GII.4 Sydney 2012 (KT239579), MNV CW1 (DQ285629), RCV Australia 1 MIC-07, (EU871528.1), RHDV Czech V351 (KF594473.1), and SaV GI Mc114 (AY237422) were expressed and purified as described (Bull et al., 2010; Urakova et al., 2016) . Mutant RdRps were generated using QuikChange site-directed mutagenesis kits (Agilent Technologies, Santa Clara, CA, USA), and confirmed by Sanger sequencing.
Quantitative RdRp activity and gel-based assays
Fluorescent activity assays were performed as described (Eltahla et al., 2013 (Eltahla et al., , 2014b . GraphPad Prism V6.05 (La Jolla, CA, USA) was used to plot the IC 50 values. Primed elongation activity was examined as in (Urakova et al., 2016) , with an RNA template modified from (Campagnola et al., 2011) , replacing six 5' ribonucleotides with 10 cytidines (PE44-NoV; Fig. 3A ). Antagonism was calculated using Compusyn software V1.0 (Chou, 2010) . JTK-109 and PPNDS were tested alone and together (4:1 ratio) against NoV GII.4 Sydney 2012 RdRp.
Inhibition of MNV plaque formation in cell culture
MNV-1 (CW1) culture assays were performed as described (Eltahla et al., 2014b) . Replication was examined using plaque assays (Rocha-Pereira et al., 2010; Schneider et al., 2012) . Cytotoxicity was examined using CellTitre Blue (Promega, Madison, WI, USA) viability assays (Eltahla et al., 2014b) .
In silico studies of the JTK-109 binding site
Molecular docking studies were performed on Viglen Genie Intel ® CoreTM i7-3770 vPro CPU@ 3.40 GHz x 8 running Ubuntu 14.04 using Molecular Operating Environment (MOE) .10 (Chemical Computing Group I, 2015 and Maestro (Schr€ odinger Release 2016-1, 2016) programs as described (Grande et al., 2016; Bassetto et al., 2016) . Briefly, a 12 Å docking grid was generated using the PPNDS structure (Site-B) as the centroid. The NoV RdRp crystal structure bound to PPNDS was downloaded from the Protein Data Bank (PDB) (RCSB, 2013a). Calicivirus RdRps (RCSB, 2013b) were aligned and superposed using the MOE2015.10 Protein Align/ Superpose tool.
Results
HCV TI-binding NNI inhibits human NoV RdRp
Six HCV NNIs were selected to represent each of the five known HCV allosteric RdRp binding sites (Fig. 1A) , including: JTK-109 (TI), Lomibuvir and Filibuvir (TII), Setrobuvir (PI), Nesbuvir (PII) and Tegobuvir (Pb) ( Table 1, Fig. 1A ). The inhibitory effects of each NNI (0.01 pMe100 mM) were quantified against human NoV GII.4 RdRp (Den Haag, 2006b) activity, using a fluorescence-based activity assay (Eltahla et al., 2013) (Fig. 1B) . Of all the NNIs tested, only the HCV RdRp TI-binder JTK-109 demonstrated significant, dosedependent inhibition of NoV RdRp activity, with an IC 50 of 12.6 mM (Fig. 1B) .
Pan-Caliciviridae antiviral activity of three HCV NNIs
NoV RdRp inhibition was observed with JTK-109, which binds in the HCV TI pocket (Hirashima et al., 2006) . Therefore, JTK-109 and two other HCV TI-binders currently in clinical trials, namely TMC-647055 (Devogelaere et al., 2012) and Beclabuvir (Gentles et al., 2014) , were selected for further assessment.
Using a quantitative fluorescent de novo RdRp assay (Eltahla et al., 2014b) , the synthesis of double-stranded RNA from a single-stranded RNA polycytidine template was monitored in the Fig. 2 , Table 2 ).
JTK-109 inhibits calicivirus RdRp primed elongation
As JTK-109 exhibited the most potent broad-spectrum inhibition in the de novo RdRp activity assays, it was examined for inhibition of primed-elongation activity using gel-shift assays (Yi et al., 2012) . The RNA template [PE44-NoV; modified from (Campagnola et al., 2011) ] allows primed transcription to extend the template from 32 to 44 nucleotides (Fig. 3A) . Elongation of PE44-NoV by the human NoV GII.4 Sydney 2012 RdRp was assessed in the presence of JTK-109 (0.1e100 mM) and the nucleoside analogue (NA) 3'dGTP (10 mM, Table 1 ) was used as a positive inhibition control (Fig. 3) . In the absence of inhibitors (0.5% DMSO [vol/vol] , vehicle only), the RNA template was extended, resulting in an upward gel shift (Fig. 3) . In the presence of JTK-109, the product formation was attenuated at 10 mM and almost completely abolished at 100 mM (Fig. 3A) . This result is consistent with the fluorescence-based NoV RdRp assay results (IC 50 4.3 mM, Table 2 ). Similar results were obtained for human NoV GII.4 Den Haag 2006b, MNV, SaV, RCV and RHDV RdRps with JTK-109 in the gel-shift assay at a fixed concentration of 100 mM (Fig. 3B) .
JTK-109 inhibits MNV replication in cell culture
Plaque reduction assays were used to further examine the antiviral activity of JTK-109. RAW264.7 cell monolayers were infected with MNV and treated with JTK-109 (0.5e10.0 mM). JTK-109 inhibited MNV plaque formation in a dose-dependent manner, with an EC 50 of 6.1 mM (95% CI: 5.1e7.3 mM, Fig. 4A and D). The NA 2CMC (Table 1 ) was used as a positive antiviral control, demonstrating complete inhibition of MNV plaque formation at Table 2. 10.0 mM (Fig. 4D ). JTK-109 had no significant effect on RAW264.7 cell viability within the concentration range examined (0.5e10.0 mM; Fig. 4B, Fig. S1 ).
The effects of JTK-109 on MNV viral titers were also examined.
JTK-109 concentrations ranged from 0.5 to 10.0 mM and were compared to the vehicle only (negative control). Viral titers (PFU/ mL) were reduced by JTK-109 treatment (relative to mock) in a step-wise fashion (Fig. 4C) , consistent with the plaque reduction assays.
Identification of a BS-AV binding pocket
The RdRp thumb domain is a highly diverse region in terms of sequence and structure (Choi et al., 2004 ) between viral families. Therefore, whilst the TI binding pocket for JTK-109 on the HCV RdRp is well defined (Kukolj et al., 2005) , it was uncertain whether it would bind to the same location in calicivirus RdRps. In silico studies using superimposition of the two RdRp crystal structures (RCSB, 2013a; RCSB, 2013b; Elhefnawi et al., 2012) , revealed that the two alpha-helices present in the HCV RdRp, which form the TI domain, were not present in the NoV RdRp. Therefore, the equivalent HCV JTK-109 binding pocket appears to be absent in the human NoV polymerase, suggesting JTK-109 binds elsewhere. Moreover, molecular docking studies of JTK-109 in the corresponding region of the NoV RdRp also found no possible binding sites.
Further molecular docking of JTK-109 on the NoV GII.4 Sydney 2012 RdRp structure identified a potential binding site spanning two previously identified NNI binding sites (Site-A and Site-B; Fig. 5A ) . The predicted binding site revealed interactions between JTK-109 moieties and highlyconserved Site-B amino acids, particularly Q414 and R419.
To validate the docked model of the JTK-109 binding pocket, we generated two RdRps with mutations proposed to be critical for binding, Q414A and R419A, which are both located in the Site-B pocket. Transcriptional activity of the mutant RdRps was (Devogelaere et al., 2012) . e IC 50 with HCV genotype 1b, Con1 RdRp (Gentles et al., 2014) . 0.1e100 mM). The nucleoside analogue 3 0 dGTP is used as a positive control (10 mM; Table 1 ) and no RdRp is used as a negative control. B) JTK-109 is assessed at a fixed concentration of 100 mM and compared to the effect of DMSO (vehicle only) against human NoV GII.4 Den Haag 2006b, MNV, SaV, RCV and RHDV RdRps. Human NoV GII.4 Sydney 2012 is used as a positive assay control with 3 0 dGTP as the inhibition control (10 mM) to demonstrate total inhibition.
confirmed, then their relative activity was examined in the presence of JTK-109 (0.1e100 mM; Fig. 5B ). These data supported the in silico study results, as both mutant RdRps were resistant to JTK-109, and neither reached 50% inhibition even at 100 mM, compared to an IC 50 of 6.3 mM against the wildtype RdRp (Fig. 5B ).
Representative RdRp structures from the Norovirus, Lagovirus
and Sapovirus genera were superimposed to reveal that Site-B is a highly-conserved RdRp pocket across the three caliciviral genera examined (Fig. 5C ). Additionally, protein alignments showed Q414 is conserved within all calicivirus RdRps examined, while R419 is conserved in the human NoV RdRps and is substituted for lysine, another basic amino acid, in all other calicivirus RdRps. These two mutations that confer resistance lie within the NoV RdRp thumb domain, but neither are located within the functional RdRp motifs, AeG (Fig. 5D ).
PPNDS is antagonistic with JTK-109 and has BS-AV activity against calicivirus RdRps
As the in silico and mutational studies revealed that JTK-109 binds within the RdRp Site-B, we predicted competitive antagonism between JTK-109 and other Site-B binding compounds such as PPNDS. Therefore, the inhibitory effects of JTK-109 (0.1e100 mM) and PPNDS (0.025e25 mM) were examined alone and together (4:1 ratio) against the transcriptional activity of the NoV GII.4 Sydney 2012 RdRp (Fig. 6A) . The average combination index of the NNIs at 50%, 75% and 90% inhibition was 3.1, confirming the two compounds were antagonistic (Fig. 6A) , indicating that both molecules bind to Site-B.
As Site-B is conserved within all calicivirus RdRps tested, PPNDS was examined for inhibitory activity against the six RdRps using a fluorescent activity assay (0.025e10 mM; Fig. 6B ). PPNDS was found to be a potent in vitro transcription inhibitor for all calicivirus RdRps (IC 50 range: 0.1e2.3 mM, Fig. 6B , Table 2 ). This was confirmed using a gel-shift assay with the human NoV GII.4 Sydney 2012 RdRp (0.01e10 mM; Fig. 6C ), and the RNA template PE44-NoV (Fig. 3A) .
PPNDS demonstrated dose-dependent inhibition, almost completely abrogating template extension activity at 10 mM. Similar results with PPNDS were obtained for human NoV GII.4 Den Haag 2006b, MNV, SaV, RCV and RHDV RdRps in the gel-shift assay at a fixed concentration of 10 mM (Fig. 6D) . However, PPNDS only demonstrated modest inhibition of MNV plaque formation in cell culture (20.5% inhibition at 10 mM, Fig. 6E ), demonstrating considerably less potency in cell-based assays compared to the in vitro fluorescence (IC 50 value: 2.3 mM) and gel-based assays.
Discussion
Despite significant research efforts, there are currently no calicivirus-specific antivirals available (Rocha-Pereira et al., 2014) . To reduce the global impact of caliciviruses, there is a demand to develop safe and effective antiviral therapies (Rohayem et al., 2010) . BS-AVs are attractive therapeutics, offering the promise of a single antiviral to combat several viral pathogens.
The two major classes of antivirals used to target viral RdRps are NNIs and NAs, with NAs already in clinical use as BS-AVs [reviewed in (Debing et al., 2015) ]. Unlike NNIs that bind allosterically, NAs mimic incoming NTPs and the RdRp erroneously incorporates them during transcription, causing chain termination (Galmarini et al., 2001) or lethal mutagenesis (Loeb et al., 1999) . This antiviral class includes ribavirin (Smith and Kirkpatrick, 1980) which is used to treat several viral infections including respiratory syncytial virus (Marcelin et al., 2014) and HCV (Reichard et al., 1993) . Similarly, Favipiravir is an approved NA for treating influenza patients in Japan (Kiso et al., 2010) and is also active against several RNA viruses in mouse models, including Ebola virus (Oestereich et al., 2014) . In addition, 2CMC has been shown in preclinical studies to inhibit the replication of several viruses including human NoV (Kolawole et al., 2016) and MNV (Rocha-Pereira et al., 2012) , as well as dengue virus, HCV, yellow fever virus and West Nile virus (Pierra et al., 2006) , amongst others. Moreover, 2CMC is probably the most promising and well-studied caliciviral antiviral, with moderate activity demonstrated in MNV cell culture (EC 50~2 mM) (RochaPereira et al., 2012) , the NoV replicon (EC 50 18 mM) (Jin et al., Table 2 . C) The effects of PPNDS on human NoV GII.4 Sydney 2012 RdRp primed elongation activity were examined using a gel shift assay. PE44-NoV (Fig. 3) RNA templates (32 nucleotides) were extended (44 nucleotides) by the RdRp without PPNDS (vehicle only) or with PPNDS (0.01e10 mM). The nucleoside analogue 3'dGTP is used as a positive control (10 mM; Table 1 ) and no RdRp (template only) was used as a negative control. D) PPNDS inhibition of caliciviral RdRp primed elongation activity was assessed at a fixed concentration of 10 mM and compared to the effect of DMSO (vehicle only) against human NoV GII.4 Den Haag 2006b, MNV, SaV, RCV and RHDV RdRps. Human NoV GII.4 Sydney 2012 is used as a positive assay control with 3'dGTP as the inhibition control (10 mM) to demonstrate total inhibition. E) The effects of PPNDS on MNV in cell culture were examined using a plaque reduction assay. Total plaque area (mm 2 ) is compared in the presence of PPNDS (0.1e10 mM) to the vehicle only (negative control) and the nucleoside analogue (2CMC, 10 mM, positive control). 2015) and more recently, in a newly developed human NoV culture system (EC 50 0.3 mM) (Kolawole et al., 2016) . However, development of 2CMC (Valopicitabine) for HCV treatment was halted following reports of undesirable gastrointestinal effects, suggesting its use for the treatment of other viruses such as human NoV, is unlikely.
The broad-spectrum antimicrobial compound, Nitazoxanide, has successfully treated a single NoV-infected patient (Siddiq et al., 2011) . Despite reported antiviral activity in vitro against the NoV replicon (IC 50 1.6 mM), influenza viruses (IC 50 range: 0.7 mMe4.9 mM), HCV genotype 1 (IC 50 0.3 mM), and HBV (IC 50 0.2 mM), amongst other viruses (Rossignol, 2014) , its mode of action
is not yet understood and further studies are needed. These BS-AVs are largely in the early stages of development and currently no calicivirus-specific antivirals are available.
Numerous antivirals have been developed against HCV, and several FDA-approved direct-acting antivirals are now available (Hepatitis C Support Project, 2016). Therefore, repurposing HCV antivirals should be considered for the treatment of other viral infections, or for use in identifying valid antiviral targets.
In this study, we identified three NNIs that bind to the HCV TI pocket, JTK-109, TMC-647055 and Beclabuvir, which demonstrated dose-dependent RdRp inhibition across the three Caliciviridae genera examined. Additionally, JTK-109 exhibited dose-dependent inhibition of both primed elongation and de novo RNA synthesis, as well as a reduction of MNV plaque formation in cell culture, but demonstrated a low therapeutic index of 4.0.
There is minimal protein sequence similarity (less than 25%) between NoV and HCV RdRps, and the thumb domain is the most diverse region (Choi et al., 2004) . Whilst the HCV RdRp features an elaborate thumb domain involved in de novo RNA synthesis, calicivirus RdRps use a protein-linked primer and template, thus requiring a wider template-binding channel (Choi et al., 2004) . Therefore, calicivirus RdRp thumb domains are smaller and less complex than the equivalent HCV RdRp region, and there is no corresponding TI binding pocket present on the NoV RdRp. Given these differences, an in silico investigation was used to identify the potential JTK-109 binding pocket on the human NoV RdRp. Docking studies revealed that JTK-109 binds in the NoV thumb domain and predominantly interacts with Site-B, through the conserved amino acids Q414 and R419, which was supported by generating drug resistant mutants. Of interest, Site-B is the same binding site reported for NAF2 and PPNDS in the human NoV RdRp, and both amino acids Q414 and R419 were shown to be involved in their binding . PPNDS and JTK-109 were antagonistic in combination, as expected for compounds that occupy the same binding site (Site-B) . Additionally, overlays of the calicivirus RdRp structures revealed that Site-B is highly-conserved within the Caliciviridae, and supporting this analysis, the Site-B binder PPNDS was a potent transcription inhibitor in all six calicivirus RdRps examined.
PPNDS has been reported as an inhibitor of Norovirus RdRp activity Croci et al., 2014b) , and this was supported in this study with additional observed inhibition of Lagovirus and Sapovirus RdRp transcriptional activities. However, PPNDS was relatively ineffective against MNV replication in cell culture. This discrepancy is likely due to its charged phosphate head that cannot pass through the cell membrane, which is reflected by the cell permeability issues observed with suramin and its other derivatives. Moreover, PPNDS exhibits non-specific inhibitory effects (Simeonov et al., 2009) , and therefore lacks the drug-like properties required for further medicinal development. In contrast, several HCV TI-binders have progressed through phase II and III clinical trials and could be further developed against other viruses using in silico drug design and structure-activity relationship chemistry to improve selectivity, cytotoxicity and potency profiles.
In conclusion, by probing caliciviral RdRps with HCV NNIs we identified three BS-AV scaffolds as potential platforms for calicivirus antiviral design. Secondly, we identified that the caliciviral RdRp Site-B is a highly-conserved, broad-spectrum target for de novo antiviral development.
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